TITLE

Charles Best--codiscoverer of insulin

AUTHOR(S)
Shampo, Marc A.; Kyle, Robert A.
PUB. DATE
December 2004
SOURCE
Mayo Clinic Proceedings;Dec2004, Vol. 79 Issue 12, p1546
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Profiles Charles Best, co-discoverer of insulin. Career history of Best; Scientists who worked with Best in developing insulin; Educational background; Impact of Best's discovery on the field of medicine.
ACCESSION #
15323759

 

Related Articles

  • Pork Mixtard 30.  // Royal Society of Medicine: Medicines;2002, p446 

    The article presents information on pork mixtard 30, a proprietary, prescription-only preparation of biphasic isophane insulin containing both isophane insulin and soluble insulin in a proportion of 70% to 30% respectively. This drug is used to treat and maintain diabetic patients, has an...

  • Citations and Clinicians' Notes: Management: Oral Hypoglycaemic Agents.  // Current Medical Literature: Diabetes;2003, Vol. 20 Issue 4, p118 

    Presents citations and clinicians' notes on the use of oral hypoglycemic agents for the management of diabetes. Efficacy and safety of combined insulin and metformin treatment in patients with type 2 diabetes; Effect of rosiglitazone in patients with type 2 diabetes mellitus; Safety and...

  • Hepatic-dependent and -independent Insulin Actions Are Impaired in the Obese Zucker Rat Model. Afonso, Ricardo A.; Ribeiro, Rogerio T.; Fernandes, Ana B.; Patarr�o, Rita S.; Macedo, M. Paula // Obesity (19307381);Feb2007, Vol. 15 Issue 2, p314 

    The article presents the research which assessed hepatic-dependent and -independent insulin actions in the obese Zucker rat model. The objective of the study was to characterize the hepatic-dependent and -independent components of whole-body insulin action in the model. In this regard,...

  • Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis. Gross, Jorge L.; Kramer, Caroline K.; Leitão, Cristiane B.; Hawkins, Neil; Viana, Luciana V.; Schaan, Beatriz D.; Pinto, Lana C.; Rodrigues, Ticiana C.; Azevedo, Mirela J. // Annals of Internal Medicine;5/17/2011, Vol. 154 Issue 10, p672 

    Background: Few studies have examined the effect of adding a third antihyperglycemic drug when blood glucose control is not achieved by using metformin and a sulfonylurea. Purpose: To compare the efficacy of add-on antihyperglycemic drugs in patients with type 2 diabetes that is not controlled...

  • Degludec: A Novel Basal Insulin. Kalra, Sanjay; Baruah, Manash P.; Niazi, Asfandyar K. // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Jan2012, Vol. 6 Issue 1, p18 

    Limitations of conventional human basal insulins like NPH have led to the development of more stable and peak less analogs. However, the first generation of basal analogs like glargine and detemir has certain shortcomings which do not allow them to be termed ideal basal insulins. Degludec, a...

  • Intensive insulin therapy reduced morbidity but not mortality in patients in the medical intensive care unit.  // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p34 

    The article presents information on a study related to intensive insulin therapy in the medical intensive care unit in Leuven, Belgium. The study was conducted by G. Van den Berghe, A. Wilmer and G. Hermans. It involved 1200 medical patients. It was found that intensive insulin therapy reduced...

  • Case Files of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: A Pediatric Exploratory Sulfonylurea Ingestion. Calello, Diane P.; Kelly, Andrea; Osterhoudt, Kevin C. // Journal of Medical Toxicology;Mar2006, Vol. 2 Issue 1, p19 

    Presents a case report of a pediatric patient who ingested a sulfonylurea-class oral hypoglycemic agent. Medical history of the patient; Information on the acute mechanism of action of sulfonylurea; Illustration of insulin secretion pathways; Epidemiology of exploratory drug ingestions by young...

  • Antidiabetic potential of oleanolic acid from Ligustrum lucidum Ait. Gao, Dawei; Li, Qingwang; Li, Ying; Liu, Zhihua; Liu, Zhiwei; Fan, Yusheng; Han, Zengsheng; Li, Jian; Li, Kun // Canadian Journal of Physiology & Pharmacology;Nov2007, Vol. 85 Issue 11, p1076 

    Ligustrum lucidum Ait. has been used in traditional Chinese medicine for over 1000 years because of its anti-tumor, antimutagenic, antidiabetic, and hepatoprotective properties. The aim of this study was to determine whether oleanolic acid (OA) is the principal active compound of L. lucidum...

  • Use of insulin glargine in dogs with diabetes mellitus. Fracassi, F.; Boretti, F. S.; Sieber-Ruckstuhl, N. S.; Reusch, C. E. // Veterinary Record: Journal of the British Veterinary Association;1/14/2012, Vol. 170 Issue 2, following p52 

    The objective of this study was to evaluate the safety and efficacy of insulin glargine in dogs with diabetes mellitus (DM). Twelve client-owned dogs with DM were included. All dogs received insulin glargine every 12 hours for at least six months, re-evaluations were performed after one, two,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics